Viscosupplementation Market Size by Product Type, Material Type, Application, End-User, Distribution Channel & Region for 2024-2031

Viscosupplementation Market Valuation- 2024-2031

The Viscosupplementation Market is increasing due to the rising prevalence of osteoarthritis and other joint disorders. Innovations in hyaluronic acid-based products are driving demand, with healthcare providers increasingly adopting these treatments for pain relief and joint function improvement. This is likely to enable the market size to surpass USD 6.5 Billion valued in 2024 to reach a valuation of aroundUSD 12.38 Billion by 2031.

Additionally, the market is seeing growth from the expanding aging population, which is driving the need for non-surgical options. Moreover, increasing awareness about viscosupplementation as a minimally invasive treatment is contributing to its popularity among patients seeking alternatives to traditional joint surgeries. The rising demand for viscosupplementation is enabling the market to grow at aCAGR of 9.24% from 2024 to 2031.

Definition/Overview

Viscosupplementation is a medical treatment involving hyaluronic acid injections into joints, increasing lubrication and cushioning. It is primarily used to manage pain and improve mobility in osteoarthritis patients.

Its use is focused on alleviating joint pain, particularly in the knee, by increasing synovial fluid. This non-surgical option is increasingly popular for managing moderate arthritis cases, driving adoption.

Future scope includes increasing advancements in hyaluronic acid formulations, driving better outcomes. The aging population and increasing demand for non-invasive treatments are contributing to the expanding market potential for viscosupplementation.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How Is the Increasing Prevalence of Osteoarthritis Driving the Growth Of The Viscosupplementation Market?

The increasing prevalence of osteoarthritis significantly drives the growth of the Viscosupplementation market by creating a higher demand for effective pain management solutions. As more individuals seek relief from joint pain and improved mobility, healthcare providers increasingly adopt viscosupplementation treatments. These minimally invasive options offer a viable alternative to surgical interventions, appealing to patients looking for effective yet less invasive approaches. Consequently, this trend supports the expansion of the market overall.

How Does the High Cost of Viscosupplementation Treatments Challenge the Growth of The Market?

The high cost of Viscosupplementation treatments poses a significant challenge to market growth by limiting accessibility for many patients. Insurance coverage discrepancies further exacerbate this issue, as not all plans provide adequate reimbursement. Consequently, patients may opt for alternative, more affordable treatments, reducing demand for viscosupplementation. This financial barrier can hinder widespread adoption among healthcare providers, ultimately impacting the overall expansion and potential of the viscosupplementation market.

Category-wise Acumens

How Will the Increasing Effectiveness of Hyaluronic Acid in Pain Management Drive the Growth of The Hyaluronic Acid-Based Product Segment?

The increasing effectiveness of hyaluronic acid in pain management will drive the growth of the hyaluronic acid-based product segment in the Viscosupplementation Market. Its ability to improve joint lubrication and mobility, particularly in osteoarthritis patients, makes it a preferred treatment option. As more healthcare providers and patients recognize its benefits in offering long-lasting relief without surgery, demand for hyaluronic acid-based products will continue to expand, supporting this segment's growth.

How Will the Growing Preference for Minimally Invasive Procedures Drive the Growth Of The Single Injection Segment?

The growing preference for minimally invasive procedures will drive the growth of the single injection segment in the Viscosupplementation Market. Single injections offer a simpler, less invasive option for osteoarthritis patients, reducing the number of hospital visits and overall discomfort. This convenience appeals to both patients and healthcare providers, enhancing its adoption. As the demand for efficient and patient-friendly treatments increases, the single injection segment is positioned for significant growth.

Country/Region-wise Acumens

Will The High Prevalence of Osteoarthritis and Advanced Healthcare Infrastructure Drive the Dominance of North America in The Viscosupplementation Market?

The high prevalence of osteoarthritis and advanced healthcare infrastructure will drive the dominance of North America in the Viscosupplementation Market. With a significant aging population, the demand for effective pain management solutions is increasing. Moreover, the region's robust healthcare system supports innovation and adoption of new treatments, allowing for better patient outcomes. The presence of leading manufacturers and strong research initiatives further enhances North America's position as a key player in this market.

Will Rising Awareness of Osteoarthritis Treatments Drive the Rapid Growth of The Asia-Pacific Region in The Viscosupplementation Market?

Increasing healthcare expenditures and rising awareness of osteoarthritis treatments will drive the rapid growth of the Asia-Pacific region in the viscosupplementation market. As more individuals become aware of effective pain management options, demand for these therapies is expected to rise. Improved healthcare infrastructure facilitates access to innovative treatments, making them more widely available. Additionally, the growing aging population in this region further contributes to the increasing need for viscosupplementation solutions, supporting market expansion.

Competitive Landscape

The viscosupplementation market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the viscosupplementation market include:

Sanofi S.A.

Anika Therapeutics, Inc.

Seikagaku Corporation

Zimmer Biomet Holdings Inc.

Smith & Nephew PLC

Ferring Pharmaceuticals B.V.

Lifecore Biomedical

Fidia Farmaceutici S.p.A.

Bioventus LLC

Johnson & Johnson Services, Inc.

Latest Developments

In September 2024, Sanofi S.A. announced a licensing agreement with RadioMedix and Orano Med for a next-generation radioligand medicine aimed at treating rare cancers, showcasing its commitment to innovative cancer therapies.

In March 2023, Seikagaku Corporation launched Hyalgan G-F 20 in Japan, a new formulation of hyaluronic acid designed for knee osteoarthritis, enhancing its product portfolio in the viscosupplementation market.

In April 2023, Zimmer Biomet Holdings Inc. received FDA 510(k) clearance for their Persona Knee Hyaluronic Acid, which is intended to provide pain relief for patients suffering from knee osteoarthritis, reflecting their focus on advancing treatment options.

In October 2023, Anika Therapeutics, Inc. reported positive results from a Phase 3 study of Qsymia, aimed at alleviating knee osteoarthritis pain, reinforcing its position in the development of effective non-surgical treatments for joint pain.